United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, llc dba vangard labs - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - because of reports of intestinal and gastric ulceration and bleeding with controlled-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. - for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leadin

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - because of reports of intestinal and gastric ulceration and bleeding with controlled-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations.     1. for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the         result of  diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia.     2. for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. in more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in such patients can produce cardiac arrest. hyperkalemia may complicate any of the following conditions: chronic renal failure, systemic acidosis, such as diabetic acidosis, acute dehydration, extensive tissue breakdown as in severe burns, adrenal insufficiency, or the administration of a potassium-sparing diuretic (e.g., spironolactone, triamterene, or amiloride) [see overdosage ]. controlled-release formulations of potassium chloride have produced esophageal ulceration in certain cardiac patients with esophageal compression due to enlarged left atrium. potassium supplementation, when indicated in such patients, should be given as a liquid preparation or as an aqueous (water) suspension of potassium chloride [see precautions: information for patients and  dosage and administration ]. all solid oral dosage forms of potassium chloride are contraindicated in any patient in whom there is structural, pathological (e.g., diabetic gastroparesis), or pharmacologic (use of anticholinergic agents or other agents with anticholinergic properties at sufficient doses to exert anticholinergic effects) cause for arrest or delay in tablet passage through the gastrointestinal tract.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - dimethyl fumarate 240mg - modified release capsule - 240 mg - active: dimethyl fumarate 240mg excipient: colloidal silicon dioxide crospovidone sheffcoat clear asa 5x00294 sheffcoat white ent tec 5x00273 capsugel green op. c162 magnesium stearate microcrystalline cellulose povidone - indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - hydrochlorothiazide, quantity: 25 mg; olmesartan medoxomil, quantity: 40 mg - tablet - excipient ingredients: lactose monohydrate; microcrystalline cellulose; hyprolose; stearic acid; magnesium stearate; purified water; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red; macrogol 400 - olmesartan medoxomil and hydrochlorothiazide is indicated for:,treatment of hypertension.,treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - hydrochlorothiazide, quantity: 12.5 mg; olmesartan medoxomil, quantity: 20 mg - tablet - excipient ingredients: lactose monohydrate; stearic acid; purified water; hyprolose; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red; macrogol 400 - olmesartan medoxomil and hydrochlorothiazide is indicated for:,treatment of hypertension.,treatment should not be initiated with this fixed dose combination.

Malta - English - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - hydrochlorothiazide, losartan potassium - film-coated tablet - hydrochlorothiazide 12.5 mg losartan potassium 50 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - hydrochlorothiazide, losartan potassium - film-coated tablet - hydrochlorothiazide 12.5 mg losartan potassium 100 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - hydrochlorothiazide, losartan potassium - film-coated tablet - hydrochlorothiazide 25 mg losartan potassium 100 mg - agents acting on the renin-angiotensin system

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - clonidine hydrochloride, quantity: 100 microgram - tablet - excipient ingredients: maize starch; hyprolose; calcium hydrogen phosphate dihydrate; lactose monohydrate; microcrystalline cellulose; allura red ac; magnesium stearate; colloidal anhydrous silica - oral: all grades of essential hypertension. renal hypertension.,the prophylactic management of migraine or recurrent vascular headaches which occur in adult patients with a frequency of more than once a month and are not adequately relieved by appropriate therapy for the acute attack. alleviation of symptoms due to localised vasodilatation in menopausal flushing.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - metformin hydrochloride, quantity: 1000 mg; sitagliptin phosphate monohydrate, quantity: 128.5 mg (equivalent: sitagliptin, qty 100 mg) - tablet, modified release - excipient ingredients: povidone; hypromellose; colloidal anhydrous silica; sodium stearylfumarate; propyl gallate; macrogol 3350; kaolin; carnauba wax; titanium dioxide; hyprolose; indigo carmine aluminium lake - janumet xr (sitagliptin phosphate monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.,[see sections 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].